Dosing Observation and Monitoring with KYNMOBI™ (apomorphine HCl)

Sunovion Answers (SA) Plus can provide support and assist with dosing observation and monitoring for KYNMOBI

To request assistance, fill out the Enrollment Form below to authorize SA Plus dosing observation and monitoring

Upon completing the Enrollment Form, SA Plus will perform benefits investigation and assist with prior authorization, as well as confirm insurance and coordinate a nurse visit with your patient.

Complete the SA Plus Enrollment Form online by clicking on the link below. Or, you may download the form and email or fax it.

SA Plus performs the benefits investigation and assists with prior authorization process [if necessary).

SA Plus performs the benefits investigation and assists with prior authorization process (if necessary)

SA Plus will contact your patient directly with a welcome call to confirm insurance, verify benefits, and coordinate a visit with a nurse for dosing observation and monitoring.

SA Plus will contact your patient directly with a welcome call to confirm insurance, verify benefits, and coordinate a visit with a nurse for dosing observation and monitoring

Dosing Observation and Monitoring Program Enrollment Form.

Dosing Observation And Monitoring with KYNMOBI

Complete the SA Plus Enrollment Form online, or download a copy and email it to enroll@sunovionplus.com or fax it to 919-518-9375

Dosing Observation And Monitoring with KYNMOBI

Complete the SA Plus Enrollment Form online, or download a copy and email it to enroll@sunovionplus.com or fax it to 919-518-9375

Download the Dosing Observation and Monitoring Program Enrollment form

Please include a copy of the patient’s prescription insurance card, if available.

Email the Enrollment Form to enroll@sunovionplus.com or fax to 919-518-9375.

The dosing observation and nurse education provided through this Program is being provided at no cost and on a complimentary basis from Sunovion in order to support access to care and appropriate care coordination. Participants in this Program agree not to submit, or cause to be submitted, any claims for payment or reimbursement to any third party payor, including any federal health care program, such as Medicare or Medicaid, for the free dose or doses of KYNMOBI received or the administration of the product through the Program.

Top

Thank you for registering at KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.